Agenus

OverviewSuggest Edit

Agenus is a clinical-stage immuno-oncology company which focuses on the discovery and development of therapies that engage the body's immune system for patients suffering with cancer. The Company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies, SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies, and phage display technologies. It is also developing checkpoint modulating antibody candidates. In addition, the Company develops cancer and tumor vaccine programs and a saponin-based vaccine adjuvant for the treatment of malaria and shingles.

TypePublic
Founded1994
HQLexington, MA, USMap
Websiteagenusbio.com
Employee Ratings3.4More
View Jobs (43)

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)328(+12%)
Job Openings43
Revenue (FY, 2020)$88.2 M(-41%)
Share Price (Sept 2021)$6.5(+3%)
Cybersecurity ratingBMore

Key People/Management at Agenus

Garo H. Armen

Garo H. Armen

Chairman and CEO
Jennifer Buell

Jennifer Buell

President and Chief Operating Officer
Donald Vidic

Donald Vidic

Vice President, Head of Commercial
Alfred Dadson

Alfred Dadson

Chief Manufacturing Officer
Christine Klaskin

Christine Klaskin

Vice President, Finance & Principal Accounting Officer
Marc van Dijk

Marc van Dijk

Chief Technology Officer
Show more

Agenus Office Locations

Agenus has offices in Lexington, Berkeley, New York and Cambridge
Lexington, MA, US (HQ)
3 Forbes Rd
Berkeley, CA, US
793 Heinz Ave
New York, NY, US
149 5th Ave #500
Cambridge, GB
315 Science Park Milton Road
Show all (4)

Agenus Financials and Metrics

Agenus Revenue

Agenus's revenue was reported to be $88.17 m in FY, 2020
USD

Revenue (FY, 2020)

88.2m

Gross profit (FY, 2020)

85.8m

Gross profit margin (FY, 2020), %

97.3%

Net income (FY, 2020)

(182.9m)

EBIT (FY, 2020)

(117.2m)

Market capitalization (9-Sept-2021)

1.3b

Closing stock price (9-Sept-2021)

6.5

Cash (31-Dec-2020)

99.9m

EV

1.3b
Agenus's current market capitalization is $1.3 b.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

16.0m3.0m7.0m24.8m22.6m42.9m36.8m150.0m88.2m

Revenue growth, %

129%256%(9%)

Cost of goods sold

672.0k536.1k2.3m

Gross profit

15.3m2.5m7.0m85.8m
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

786.4k653.7k2.8m13.4m626.8k868.8k1.1m807.4k736.0k720.9k3.1m1.6m4.0m6.4m6.8m6.0m6.6m4.4m27.0m4.2m3.4m1.6m15.9m12.8m79.9m15.7m19.9m15.1m26.9m

Cost of goods sold

23.7k128.5k217.2k272.8k176.7k80.1k634.0k

Gross profit

786.4k653.7k2.8m13.4m498.3k651.6k836.5k630.7k655.9k720.9k3.1m1.6m26.3m

Gross profit Margin, %

100%100%100%100%80%75%75%78%89%100%100%100%98%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

21.5m27.4m25.7m136.7m71.4m60.2m53.1m61.8m99.9m

Accounts Receivable

552.3k1.2k9.8m11.4m1.1m938.1k16.3m1.2m

Prepaid Expenses

545.9k658.4k1.2m2.0m11.1m19.3m7.4m10.7m

Inventories

16.0k95.7k88.2k88.2k79.5k55.5k
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

12.0m14.7m10.7m24.6m25.5m24.8m17.2m13.4m30.2m73.5m48.3m38.4m79.3m124.7m184.1m78.3m73.4m75.4m113.9m81.8m65.1m52.3m43.2m46.2m158.3m121.7m93.3m92.3m79.2m

Accounts Receivable

188.058.7k92.3k369.1k163.7k202.5k1.1k2.5m4.1m7.3m10.2m9.4m10.3m6.8m3.9m2.2m1.1m10.9m6.1m796.0k2.2m2.3m2.6m16.6m

Prepaid Expenses

830.7k771.6k536.3k804.5k691.5k631.8k887.6k738.8k655.2k1.3m1.1m1.4m2.5m1.8m2.0m2.8m2.8m3.0m6.6m8.9m10.8m11.1m12.9m14.5m18.1m13.6m10.4m6.9m7.7m

Inventories

26.4k26.4k20.1k18.6k18.6k16.0k16.0k4.0k3.3k95.7k95.7k88.2k88.2k88.2k88.2k88.2k88.2k87.5k87.0k80.2k62.2k55.5k55.5k55.0k55.0k55.0k
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(11.3m)(30.1m)(42.5m)(87.9m)(127.0m)(120.7m)(162.0m)(111.6m)(182.9m)

Depreciation and Amortization

1.6m586.3k1.6m2.0m4.9m6.0m6.3m6.7m7.2m

Inventories

4.1k16.0k(95.7k)7.5k8.7k24.0k55.0k

Accounts Payable

(181.8k)189.6k(45.9k)2.7m419.7k1.6m5.4m(234.0k)2.8m
Quarterly
USDQ2, 2011Q3, 2011Q4, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(11.7m)(17.3m)(23.3m)6.8m(155.4k)(5.9m)(5.8m)(17.0m)(24.3m)(357.5k)(8.4m)(16.5m)(18.7m)(59.2m)(72.3m)(31.8m)(60.1m)(100.9m)(17.1m)(48.8m)(85.7m)(54.3m)(79.5m)(113.2m)17.4m(34.4m)(80.7m)(45.3m)(93.5m)

Depreciation and Amortization

1.1m1.7m2.3m549.8k1.1m1.5m147.0k312.0k448.2k266.5k589.4k1.0m445.5k885.5k1.4m1.2m2.5m3.7m1.5m3.1m4.6m1.6m3.1m4.7m1.6m3.3m5.0m1.7m3.5m

Inventories

6.4k1.5k1.5k4.1k(12.0k)(12.7k)(95.7k)(95.7k)7.5k7.5k7.5k8.0k17.3k24.0k24.0k

Accounts Payable

(358.5k)(215.2k)105.7k(467.5k)(175.9k)(340.1k)(149.7k)(242.1k)(269.4k)184.0k(562.1k)35.2k2.3m797.8k1.3m(2.3m)474.5k(1.3m)(1.1m)(1.2m)1.0m(2.8m)1.7m2.9m(860.0k)5.6m3.1m1.2m6.1m
show all
USDQ2, 2011

Financial Leverage

-1.3 x
Show all financial metrics

Agenus Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

Learn more about our premium products
SecurityScorecard logo

Agenus Online and Social Media Presence

Agenus's Trends

Embed Graph

Agenus News and Updates

September 10, 2021

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks

LEXINGTON, Mass. and BOSTON, Sept. 10, 2021 /PRNewswire/ -- Agenus Inc. ("Agenus"), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections today announced the...
September 09, 2021

Agenus to Participate in September Investor Conferences

LEXINGTON, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell, P…
August 09, 2021

Agenus Corporate Update and Second Quarter 2021 Financial Report

LEXINGTON, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update …
July 09, 2021

Agenus Acquires 120 Acres in the Heart of the California Biomanufacturing Center in Vacaville

VACAVILLE, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. has purchased 120-acres in Vacaville’s California Biomanufacturing Center from housing developer A.G. Spanos, a transaction that represents a major advance in the city’s plans to expand its biotechnology footprint and solidify itself…
July 06, 2021

Agenus says its Bristol Myers Squibb licensing deal has up to $1.3 billion in milestone payments

Shares of Agenus Inc. were up 2.0% in premarket trading on Tuesday after the company said a licensing deal with Bristol Myers Squibb Co. had closed. As part of the agreement, Bristol plans to study an experimental Agenus immuno-oncology drug as a treatment for non-small cell lung cancer. Bristol w…
July 06, 2021

Agenus Closes $200M Upfront BMS Collaboration and Announces FDA Acceptance of IND for Partnered Anti-TIGIT Bispecific Antibody, AGEN1777

LEXINGTON, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announ…
Show more

Agenus Blogs

September 16, 2021

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO

Objective response rate of 33% and median duration of response not reached with 19.4 months median follow-up in PD-L1+ tumors; expands benefit of anti-PD-1 alone Improved responses seen across all histology subgroups including populations of patients unresponsive to other therapies Dr.
August 26, 2021

Balstilimab Monotherapy Data Published in Gynecologic Oncology

Balstilimab Monotherapy Data Published in Gynecologic Oncology Content Import Thu, 08/26/2021 - 09:00 Balstilimab Monotherapy Data Published in Gynecologic Oncology August 26, 2021 This release is a backfill from a News Wire General Rele…
August 02, 2021

Agenus to Participate in the BTIG Virtual Biotechnology Conference 2021

LEXINGTON, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that Jennifer Buell,
July 26, 2021

Agenus to Provide Corporate Update and Second Quarter 2021 Financial Report

Conference Call on Monday, August 9, 2021, at 8:30 a.m. ET LEXINGTON, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to
April 28, 2021

Agenus to Present at the 2021 ASCO Annual Meeting

LEXINGTON, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced that it will give two
April 22, 2021

Agenus to Provide Corporate Update and First Quarter 2021 Financial Report

Conference Call on Thursday, May 6, 2021 at 8:30 a.m. ET LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to
Show more

 Agenus Frequently Asked Questions

  • When was Agenus founded?

    Agenus was founded in 1994.

  • Who are Agenus key executives?

    Agenus's key executives are Garo H. Armen, Jennifer Buell and Donald Vidic.

  • How many employees does Agenus have?

    Agenus has 328 employees.

  • What is Agenus revenue?

    Latest Agenus annual revenue is $88.2 m.

  • What is Agenus revenue per employee?

    Latest Agenus revenue per employee is $268.8 k.

  • Who are Agenus competitors?

    Competitors of Agenus include Lyell, Halozyme Therapeutics and MultiVir.

  • Where is Agenus headquarters?

    Agenus headquarters is located at 3 Forbes Rd, Lexington.

  • Where are Agenus offices?

    Agenus has offices in Lexington, Berkeley, New York and Cambridge.

  • How many offices does Agenus have?

    Agenus has 4 offices.